Drug Profile
Research programme: hepatitis B and C inhibitors - Fusogen
Alternative Names: fusolin; fusopinLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator FusoGen Pharmaceuticals
- Class Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-B in China
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in China
- 05 Jul 2006 Preclinical trials in Hepatitis B treatment in China (unspecified route)